| Application no. and date | 15151165.6 (espacenet) (Federated) (European Patent Register), 20091119 | | Patent/reg. no. and date | DK/EP 2889033, 20180321 | | Publication date | 20150701 | | Priority no. and date | US 116106 P, 20081119 | | EP pub. no. and date |
EP 2889033 20150701 | | Effective date | | | Applicant/owner | Forum Pharmaceuticals Inc., 225 Second Avenue
Waltham, MA 02451, US | | Applicant ref. no. | ROI EP2889033[013171-0021] | | Inventor | Koenig, Gerhard, 1662 Commonwealth Ave.
Newton, MA Massachusetts 02465, US,
Shapiro, Gideon, 5507 NW 80th Avenue
Gainsville, FL Florida 32653, US,
Chesworth, Richard, 88 Kingston Stree Unit 5F
Boston, MA Massachusetts 02111, US | | Representative | RWS Group, Europa House
Chiltern Park, Chiltern Hill
Chalfont St Peter
Bucks SL9 9FG, GB | | Opponent | | | IPC Class | A61K 31/439 (2006.01) , A61P 25/00 (2006.01) | | Title | Behandling af negative symptomer på skizofreni med (R)-7-chlor-N-(quinuclidin-3-yl)benzo[b]thiophen-2-carboxamid og farmaceutisk acceptable salte deraf | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
